PROGRESSIVE CORP/OH/ (PGR): what the price requires

At today's price, PROGRESSIVE CORP/OH/ (PGR) is priced for 21.9% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-13 · Source: https://boothcheck.com/report/PGR

Headline

FieldValue
TickerPGR
CompanyPROGRESSIVE CORP/OH/
Current price$233.55/sh
CompositionPersonal Lines 87% / Commercial Lines 13%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Elite ROE must persist for19.1y before normalizing (held at the 19% elite tier)
Perpetuity-equivalent ROE21.9%
Return on equity now37.3%
ROE gap-15.4pp
Price-to-book4.26x

Solve inputs: computed at a 8.2% cost of equity; ROE searched up to the 19% ROE ceiling; each 1pp moves the implied horizon ~2.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~22 years; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.20σ
cohort percentile (of 80 peers)85
sustained it ~10 years at this level50%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.10x3expensive
Earnings0.73x2justifies
Relative0.34x3justifies
Growth0.58x2justifies

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.7%); the inversion above states its own rate.

Per-Model Detail (n=10)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$399.190.59xyesTBVPS $54.59 × 7.31x (ROE (TTM) 36.1% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption))
Relative ValuationRelative$247.170.94xyesP/E 11x (sector median), scenarios: 9.1x / 11.0x / 12.9x (bear / base = sector held flat / bull), EV/EBITDA 22x
Simple DDMGrowth——no—
Two-Stage DDMGrowth$1926.820.12xyesStage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$212.921.10xyesBV/sh $54.59, ROE (TTM) 36.1%, ke 9.3%
Two-Stage Excess ReturnAsset$452.770.52xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$225.771.03xyesRev $89.5B, growth 14% (input: historical growth; tapered), Terminal P/S: 1.3x / 1.5x / 1.8x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$688.100.34xyesEPS $19.66, growth 35% (input: historical EPS growth), PEG=0.34 (Undervalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$155.401.50xyes√(22.5 × EPS $19.66 × BVPS $54.59) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$634.360.37xyesEPS $19.66 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$737.250.32xyesEPS $19.66 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$212.541.10xyesEPS $19.66 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (dilution)0.0%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

Progressive is a mature franchise running at a stage of profitability most insurers reach only in their best year, and the numbers should be read in that light. A property-casualty insurer makes money two ways: underwriting (taking in more premium than it pays out in claims and expenses) and investing the float in between. Progressive is winning on the first lever in a way the industry almost never sees sustained. The 10-K defines underwriting profit as net premiums earned plus fees, less losses, loss-adjustment expenses, acquisition costs, and other underwriting expenses; in the year to date through March, that calculation produced a combined ratio of 86.4, meaning the company kept roughly 14 cents of underwriting profit on every premium dollar before a cent of investment income. That is not a normal personal-auto result. It is among the best the line has produced in decades.

What turns that underwriting edge into a compounding machine is growth on top of it. May 2026 alone showed net premiums written of about $7.0 billion, up 6%, with policies in force up 8% to roughly 40 million, and net income of about $1.45 billion, up 36% year over year. An insurer growing the book 8% while running a combined ratio in the low 80s is doing the two hard things at once: writing more business and writing it profitably. Progressive's direct-to-consumer model and its segmentation are the engine, and the 10-K notes it keeps pushing the mix, with about 10% of core commercial auto premiums now written through the direct channel.

The return on equity the business actually earns is the cleanest summary of the bull case. Progressive is generating a return on equity around 37%, against a price that requires the company to sustain roughly 20% to justify itself. That gap is wide. The capital-return capacity that follows is real: the share count is flat, the company carries no funding stress that applies to an operating-leverage frame, and earnings of this size give management room to return capital through dividends and buybacks while still funding growth. A holder is buying the best-underwriting auto insurer in the country at a moment when both the underwriting and the growth are firing together.

Bear Case

The variable with the most leverage on Progressive's thesis is loss-cost inflation, and the current combined ratio is the cyclical peak, not the baseline. The 10-K is explicit about what drives the cost side: claims costs "are a function of loss severity and frequency and, for our personal auto and core commercial auto businesses, are influenced by inflation and driving" patterns. A combined ratio in the low-to-mid 80s today reflects a benign window in which Progressive priced ahead of a loss-cost spike that has since cooled. The next leg of the cycle works the other way. When repair costs, medical severity, or accident frequency reaccelerate, regulators who must approve rate filings can lag the reality, and the gap between adequate rates and filed rates is exactly where an auto insurer's margin gets squeezed. The current ratio cannot be extrapolated; the industry runs personal auto closer to the low-90s in a normal year, and the math from here is mean reversion toward that, not extension of the present peak.

The price has a second sensitivity that compounds the first: it requires Progressive to keep earning far above the industry's long-run return. The stock trades around $205 (as of June 27, 2026), near 3.7 times book value, and the only way a P/B that high is supported is a sustained return on equity well above the cost of equity. The price needs roughly a 20% return on equity to hold; Progressive earns about 37% today. The bear case is not that the company is failing. It is that 37% is a peak-cycle return, the kind that competition and loss-cost normalization erode, and if the sustainable return drifts back toward the high teens, the multiple the market is paying compresses with it. Pay 3.7 times book for an insurer and you are betting this particular one out-earns its peers for a very long time.

The structural risk underneath both is reserving and catastrophe exposure. The 10-K names loss-and-LAE reserves as the estimate "most critical with respect to the application of estimates and assumptions," the company's "best estimate of our ultimate liability for losses." Reserves are an estimate, and an insurer that grows its book 8% a year is writing a larger and larger volume of policies whose ultimate cost is not yet known. A severe-weather year, a burst of social inflation in bodily-injury claims, or an adverse reserve development would hit the combined ratio directly, and the price, which embeds today's exceptional underwriting as if it were durable, has little cushion for that. The balance sheet is sound and the float is well managed; the risk is not solvency but the durability of a return the market is capitalizing at a premium.

Valuation

For an insurer, the price reduces to one question: what return on equity does it require, and can the company hold it? At about $205, Progressive trades near 3.7 times book value, and a multiple that rich only makes sense if the business sustains a return on equity well above its cost of capital. The price embeds roughly a 20% return on equity, carried for a long horizon. Progressive currently earns about 37%. The reassuring read is that the price asks for far less than the company delivers today; the demanding read is that 37% is a peak-cycle number and the gap is exactly the cushion that loss-cost normalization and competition tend to close.

Where does the price sit against the methods? Unusually for a stock this expensive on book, it is supported rather than stretched. The asset-value lens lands right at the price, the earnings-power and growth lenses land somewhat below it, and the relative-multiple lens against insurance peers actually sits well under the price, reflecting how much better Progressive's economics are than the cohort. No family of method calls the stock a bet beyond what standard frames support; this is a value-and-asset-supported name whose premium is earned by genuinely superior underwriting, not a pure growth wager. The peer set here, FAF, FNF, and FG, is title and life-oriented and a poor economic match for a personal-auto underwriter, so the relevant comparison is Progressive against its own combined ratio and return on equity, both of which sit at the favorable end of anything the industry produces.

The solvency frame for a financial is not net debt or cash burn, which do not apply to a float-funded balance sheet; it is regulatory-capital and payout capacity. On that score Progressive is comfortable: earnings near $1.45 billion in a single month, a flat share count, and underwriting profitability that funds both growth and capital return. The honest tension in the valuation is durability, not solvency. The reported numbers are excellent and the price does not require them to stay this excellent. What it does require is that the return on equity not fall back toward the high teens faster than book value compounds, and the combined ratio sitting at a multi-decade-best level is the reminder that the favorable inputs are cyclical.

Catalysts

Progressive reports monthly, so the catalyst cadence is unusually frequent and unusually clean. The May 2026 update was the standout: net premiums written of about $7.0 billion, up 6%; net premiums earned up 10% to roughly $7.3 billion; policies in force up 8% to about 40 million; and net income of about $1.45 billion, a 36% jump year over year, with a May combined ratio of 82.1, down 4.8 points from a year earlier. The market read it as confirmation that premium growth, earnings, and underwriting profitability are all improving together, and the stock rose on the print.

The first-quarter picture set the tone. For the year to date through March, net premiums written reached $23.6 billion, up 6%, net premiums earned were $21.0 billion, up 8%, and net income was $2.8 billion, up 10%, with a companywide combined ratio of 86.4. The monthly March combined ratio of 88.8 improved 2.1 points from the prior-year period, which matters because March carries more weather exposure than the calmer winter months, so holding underwriting profit through it is a sign the pricing is keeping pace with loss costs rather than lagging them.

The forward watch items are loss-cost trends and the rate environment. Rating agencies hold a broadly stable outlook on US personal lines, citing improved pricing adequacy and stronger returns on equity across the sector, which is the macro tailwind behind Progressive's current numbers. The risk to monitor in coming prints is the point at which that adequacy narrows: if severity or frequency reaccelerates and filed rates lag, the combined ratio drifts up from today's exceptional level toward the industry's more normal low-90s. The monthly releases make that turn visible earlier here than at almost any other insurer.

Peer Cohorts (Per Segment, With Filing Citations)

Personal Lines (reported)

Commercial Lines (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

PGR February 2026 8-K · PGR May 2026 8-K · PGR Q1 2026 results, March 2026

View the full interactive PGR report on boothcheck